Patents by Inventor Pablo Umaña

Pablo Umaña has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND 4-1BB (CD137) AGONISTS
    Publication number: 20240109976
    Abstract: The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1 BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: June 13, 2023
    Publication date: April 4, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Claudia Ferrera Koller, Christian Klein, Mario Perro, Johannes Sam, Pablo Umaña, Wei Xu
  • COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS
    Publication number: 20240100063
    Abstract: The present invention relates to combination therapies employing PD-1 axis binding antagonists and LRRK2 inhibitors and, and the use of these combination therapies for the treatment of cancer.
    Type: Application
    Filed: April 20, 2023
    Publication date: March 28, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Denise Corti, Stephan Gasser, Gabor Gyulveszi, Claudio Murgia, Tobias Schmidt, Martha Liliana Serrano Serrano, Pablo Umaña
  • COMBINATION THERAPY OF PD-1-TARGETED IL-2 VARIANT IMMUNOCONJUGATES AND FAP/4-1BB BINDING MOLECULES
    Publication number: 20240092856
    Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunoconjugates with specific antibodies which bind human FAP and 4-1BB and optionally with an anti-CEA/anti-CD3 bispecific antibody.
    Type: Application
    Filed: March 8, 2022
    Publication date: March 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Christina CLAUS, Laura CODARRI DEAK, Sara COLOMBETTI, Christian KLEIN, Valeria G. NICOLINI, Mario PERRO, Johannes SAM, Christine TRUMPFHELLER, Pablo UMAÑA
  • PH-DEPENDENT MUTANT INTERLEUKIN-2 POLYPEPTIDES
    Publication number: 20240092853
    Abstract: The present invention generally relates to pH-dependent mutant interleukin-2 polypeptides that exhibit reduced IL-2 receptor binding at neutral pH and retained IL-2 receptor binding at reduced pH. In addition, the invention relates to immunoconjugates comprising said pH-dependent mutant IL-2 polypeptides, polynucleotide molecules encoding the pH-dependent mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the pH-dependent mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: December 2, 2021
    Publication date: March 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lorenzo DEHO, Christian GASSNER, Sylvia HERTER, Thomas HOFER, Ralf HOSSE, Adrian HUGENMATTER, Christian KLEIN, Florian LIMANI, Ekkehard MOESSNER, Melanie OBBA, Bianca SCHERER, Pablo UMANA
  • Antibodies binding to NKG2D
    Publication number: 20240067734
    Abstract: The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: October 24, 2023
    Publication date: February 29, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Guy GEORGES, Ralf HOSSE, Inja WALDHAUER, Christian KLEIN, Pablo UMANA
  • ANTIBODIES BINDING TO CD3
    Publication number: 20240042022
    Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: September 8, 2023
    Publication date: February 8, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Anne FREIMOSER-GRUNDSCHOBER, Thomas HOFER, Ralf HOSSE, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMAÑA, Inja WALDHAUER, Wolfgang RICHTER, Alexander KNAUPP, Halina TROCHANOWSKA
  • IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULES
    Publication number: 20240043535
    Abstract: The present invention generally relates to novel immune activating Fc domain binding molecules for activation of immune cells and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: December 16, 2022
    Publication date: February 8, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Alejandro Carpy Gutierrez Cirlos, Christina Claus, Laura Codarri Deak, Diana Darowski, Tanja Fauti, Claudia Ferrara Koller, Anne Freimoser-Grundschober, Sylvia Herter, Thomas Hofer, Christian Klein, Laura Lauener, Stephane Leclair, Ekkehard Moessner, Christiane Neumann, Pablo Umaña, Ali Bransi, Marlena Surówka
  • Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
    Patent number: 11865082
    Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L1.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: January 9, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Douglas Hanahan, Christian Klein, Valeria Nicolini, Pablo Umana, Stephan Wullschleger
  • TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES
    Publication number: 20230416365
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: November 17, 2022
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy GEORGES, Thomas HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Pablo UMAÑA, Jenny THOM, Stephan GASSER, Jean-Baptiste VALLIER, Tanja FAUTI
  • ANTI-CD3/ANTI-CD28 BISPECIFIC ANTIGEN BINDING MOLECULES
    Publication number: 20230416366
    Abstract: The present invention relates to anti-CD3/anti-CD28 bispecific antigen binding molecules and masked protease activated forms thereof, methods for their production, pharmaceutical compositions containing these molecules, and their use as immunomodulators and/or costiumulators in the treatment of a disease, in particular cancer.
    Type: Application
    Filed: December 21, 2022
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Martina GEIGER, Thomas HOFER, Christian KLEIN, Pablo UMAÑA
  • PREVENTION OR MITIGATION OF T-CELL ENGAGING AGENT-RELATED ADVERSE EFFECTS
    Publication number: 20230416412
    Abstract: The present invention relates to the prevention or mitigation of adverse effects related to T cell engaging agents, such as cytokine release syndrome. Specifically, the invention relates to the prevention or mitigation of such side effects using an inhibitor of NACHT, LRR and PYD domains-containing protein 3 (NLRP3).
    Type: Application
    Filed: May 26, 2023
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Gabrielle LECLERCQ-COHEN, Johannes SAM, Nathalie STEINHOFF, Pablo UMAÑA
  • Antibodies binding to NKG2D
    Patent number: 11827711
    Abstract: The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: November 28, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Ralf Hosse, Inja Waldhauer, Christian Klein, Pablo Umana
  • TREATMENT METHOD
    Publication number: 20230372479
    Abstract: The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent. The invention further relates to methods of treating a disease, particularly a B-cell proliferative disorder, and methods for reduction of adverse effects in response to the administration of a therapeutic agent, particularly a T-cell activating therapeutic agent.
    Type: Application
    Filed: December 1, 2022
    Publication date: November 23, 2023
    Inventors: Marina BACAC, Stefan EVERS, Christian KLEIN, Pavel PISA, Eva ROSSMANN, Jose SARO, Pablo UMANA
  • ANTI-CEA ANTIBODIES
    Publication number: 20230365711
    Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
    Type: Application
    Filed: March 9, 2023
    Publication date: November 16, 2023
    Applicant: Roche Glycart AG
    Inventors: Thomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
  • COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS
    Publication number: 20230357397
    Abstract: The present invention relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies and/or agents blocking PD-L1/PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: February 9, 2023
    Publication date: November 9, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Christina CLAUS, Claudia FERRARA KOLLER, Christian KLEIN, Sabine LANG, Viktor LEVITSKI, Pablo UMAÑA
  • COMBINATION THERAPY OF TUMOR TARGETED ICOS AGONISTS WITH T-CELL BISPECIFIC MOLECULES
    Publication number: 20230355754
    Abstract: The present invention relates to agonistic ICOS-binding molecules comprising at least one antigen binding domain that binds to a tumor-associated antigen and their use in combination with T-cell bispecific molecules in the treatment of cancer, the agonistic ICOS-binding molecules as such, pharmaceutical compositions comprising these molecules, and methods of using the same.
    Type: Application
    Filed: March 6, 2023
    Publication date: November 9, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Tanja FAUTI, Christian KLEIN, Johannes SAM, Pablo UMANA, Ramona MURR, Joerg ZIELONKA, Lucas HABEGGER
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20230340160
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: April 17, 2023
    Publication date: October 26, 2023
    Inventors: Oliver AST, Peter BRUENKER, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
  • COMBINATION THERAPY WITH FAP-TARGETED CD40 AGONISTS
    Publication number: 20230340154
    Abstract: The present invention relates to combination therapies employing FAP-targeted CD40 agonists, in particular bispecific antigen binding molecules comprising at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) and at least one antigen binding domain capable of specific binding to CD40, and radiotherapy.
    Type: Application
    Filed: May 16, 2023
    Publication date: October 26, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sara Labiano Alminana, Pedro Romero, Genrich Tolstonog, Christine Trumpfheller, Pablo Umana, Marie Catherine Vozenin
  • Bispecific HER2 antibodies and methods of use
    Patent number: 11787873
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: October 17, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • MONOCLONAL ANTIBODIES AGAINST BCMA
    Publication number: 20230322957
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Application
    Filed: November 21, 2022
    Publication date: October 12, 2023
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl